In the Claims

1. (Currently amended) A ~~fusion partner protein~~ polypeptide of no more than 140 amino acids comprising a choline binding domain of SEQ ID NO:8, wherein a ~~and a heterologous promiscuous~~ T helper epitope from Tetanus toxin is inserted into said SEQ ID NO:8.

2. (Withdrawn) A fusion partner protein according to claim 1 wherein the choline binding domain is derived from the C terminus of LytA.

3. (Withdrawn) A fusion partner protein according to claim 2 wherein the C-LytA or derivatives comprises at least four repeats of any of SEQ ID NO: 1 to 6.

4. (Withdrawn) A fusion partner protein according to claim 1, wherein the choline binding domain is selected from the group of:
   a) the C-terminal domain of LytA as set forth in SEQ ID NO:7;
   b) the sequence of SEQ ID NO:8;
   c) a peptide sequence comprising an amino acid sequence having at least 85% identity to any of SEQ ID NO:1 to 6; and
   d) a peptide sequence comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:8.

5. (Currently amended) A fusion ~~partner~~ protein comprising a polypeptide as claimed in claim 1 and further comprising a heterologous protein.

6. (Currently amended) A fusion protein as claimed in claim 5 wherein the heterologous protein is chemically conjugated to said polypeptide ~~the fusion partner~~.

7. (Currently amended) A fusion protein as claimed in claim 5 wherein the heterologous protein is derived from an organism selected from the following group: Human Immunodeficiency virus HIV-1, human herpes simplex viruses, cytomegalovirus, Rotavirus, Epstein Barr virus, Varicella Zoster Virus, hepatitis A virus, hepatitis C virus, hepatitis E virus, ~~from~~ Respiratory Syncytial virus, parainfluenza virus, measles virus, mumps virus, human papilloma viruses, flaviviruses, ~~and~~ Influenza virus, ~~from~~ Neisseria species ~~spp~~, Moraxella species ~~spp~~, Bordetella species ~~spp~~; Mycobacterium species ~~spp~~, Mycobacterium ~~M.~~ tuberculosis; Escherichia species ~~spp~~, enterotoxic Escherichia ~~E.~~ coli; Salmonella species ~~spp~~,; Listeria species ~~spp~~; Helicobacter species ~~spp~~; Staphylococcus species ~~spp~~., Staphylococcus ~~S.~~ aureus, Staphylococcus ~~S.~~ epidermidis; Borrelia species ~~spp~~; Chlamydia species ~~spp~~, Chlamydia ~~C.~~ trachomatis, Chlamydia ~~C.~~ pneumoniae; Plasmodium species ~~spp~~, Plasmodium ~~P.~~ falciparum; Toxoplasma species ~~spp~~, or Candida species ~~spp~~.

8. (Currently amended) A fusion protein as claimed in claim 5 wherein the heterologous protein is selected from a tumour associated protein , an immunogenic fragment of a tumor associated protein, a ~~or~~ tissue specific protein , and an ~~or~~ immunogenic fragment of a tissue specific protein ~~thereof~~.

9. (Currently amended) A fusion protein as claimed in claim 8 wherein the heterologous protein ~~or fragment thereof~~ is selected from MAGE 1, MAGE 3, MAGE 4, PRAME, BAGE, LAGE 1, LAGE 2, SAGE, HAGE, XAGE, PSA, PAP, PSCA, prostein, P501S, HASH2, Cripto, B726, NY-BR1.1, P510, MUC-1, Prostase, STEAP, tyrosinase, telomerase, survivin, CASB616, P53, and ~~or~~ her 2 neu , or an immunogenic fragment thereof .

10. (Previously presented) A fusion protein as claimed in claim 6 further comprising an affinity tag of at least 4 histidine residues.

11. (Currently amended) A nucleic acid sequence encoding a polypeptide ~~protein~~ of claim 1.

12. (Original) An expression vector comprising a nucleic acid sequence of claim 11.

13. (Previously presented) A host cell transformed with an expression vector of claim 12.

14. (Currently amended) An immunogenic composition comprising a fusion protein ~~protein~~ as claimed in claim 5 ~~claim 1~~ and a pharmaceutically acceptable excipient.

15. (Original) An immunogenic composition as claimed in claim 14 which additionally comprises a TH-1 inducing adjuvant.

16. (Original) An immunogenic composition as claimed in claim 15 in which the TH-1 inducing adjuvant is selected from the group of adjuvants comprising: 3D-MPL, QS21, a mixture of QS21 and cholesterol, a CpG oligonucleotide or a mixture of two or more said adjuvants.

17. (Previously presented) A process for the preparation of a immunogenic composition, comprising admixing the fusion protein of claim 6 with a suitable adjuvant, diluent or other pharmaceutically acceptable carrier.

18. (Currently amended) A process for producing a polypeptide ~~fusion protein~~ of claim 1 comprising culturing a host cell comprising a vector encoding said polypeptide ~~fusion protein~~ under conditions sufficient for the production of said polypeptide ~~fusion protein~~ and recovering the polypeptide ~~fusion protein~~ from the culture medium.

19. (Currently amended) A pharmaceutical composition comprising a fusion protein ~~fusion protein~~ of claim 5 ~~claim 1~~.

20.-25. (Canceled)

26. -35. (Withdrawn)

36. (New) A polypeptide according to claim 1 where said T helper epitope is selected from the P2 and P30 epitopes of tetanus toxoid.

37. (New) A polypeptide according to claim 36 consisting of amino acid residues 5-133 of SEQ ID NO:27.

38. (New) A fusion protein comprising a polypeptide of claim 36 and a heterologous protein.